Minireview: Gut peptides: Targets for antiobesity drug development?

Timothy H Moran, Megan J. Dailey

Research output: Contribution to journalArticle

Abstract

Gut peptides play multiple roles in the controls of gastrointestinal function and in the initiation and termination of meals. Plasma levels of these peptides are differentially affected by the presence of nutrients in the digestive tract, and the patterns of peptide release are consistent with both their feeding stimulatory and inhibitory actions. A number of these peptide systems have been investigated as potential targets for antiobesity drug development. Progress has been made in developing long-acting peptide analogs and, in some cases, nonpeptide agonists and antagonists. Whether any individual approach will have significant long-term efficacy remains to be demonstrated. Approaches that target multiple systems may hold the most promise.

Original languageEnglish (US)
Pages (from-to)2526-2530
Number of pages5
JournalEndocrinology
Volume150
Issue number6
DOIs
StatePublished - Jun 2009

Fingerprint

Anti-Obesity Agents
Peptides
Meals
Gastrointestinal Tract
Food

ASJC Scopus subject areas

  • Endocrinology

Cite this

Minireview : Gut peptides: Targets for antiobesity drug development? / Moran, Timothy H; Dailey, Megan J.

In: Endocrinology, Vol. 150, No. 6, 06.2009, p. 2526-2530.

Research output: Contribution to journalArticle

Moran, Timothy H ; Dailey, Megan J. / Minireview : Gut peptides: Targets for antiobesity drug development?. In: Endocrinology. 2009 ; Vol. 150, No. 6. pp. 2526-2530.
@article{a17cadead59640929754b1aa9468111a,
title = "Minireview: Gut peptides: Targets for antiobesity drug development?",
abstract = "Gut peptides play multiple roles in the controls of gastrointestinal function and in the initiation and termination of meals. Plasma levels of these peptides are differentially affected by the presence of nutrients in the digestive tract, and the patterns of peptide release are consistent with both their feeding stimulatory and inhibitory actions. A number of these peptide systems have been investigated as potential targets for antiobesity drug development. Progress has been made in developing long-acting peptide analogs and, in some cases, nonpeptide agonists and antagonists. Whether any individual approach will have significant long-term efficacy remains to be demonstrated. Approaches that target multiple systems may hold the most promise.",
author = "Moran, {Timothy H} and Dailey, {Megan J.}",
year = "2009",
month = "6",
doi = "10.1210/en.2009-0003",
language = "English (US)",
volume = "150",
pages = "2526--2530",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Minireview

T2 - Gut peptides: Targets for antiobesity drug development?

AU - Moran, Timothy H

AU - Dailey, Megan J.

PY - 2009/6

Y1 - 2009/6

N2 - Gut peptides play multiple roles in the controls of gastrointestinal function and in the initiation and termination of meals. Plasma levels of these peptides are differentially affected by the presence of nutrients in the digestive tract, and the patterns of peptide release are consistent with both their feeding stimulatory and inhibitory actions. A number of these peptide systems have been investigated as potential targets for antiobesity drug development. Progress has been made in developing long-acting peptide analogs and, in some cases, nonpeptide agonists and antagonists. Whether any individual approach will have significant long-term efficacy remains to be demonstrated. Approaches that target multiple systems may hold the most promise.

AB - Gut peptides play multiple roles in the controls of gastrointestinal function and in the initiation and termination of meals. Plasma levels of these peptides are differentially affected by the presence of nutrients in the digestive tract, and the patterns of peptide release are consistent with both their feeding stimulatory and inhibitory actions. A number of these peptide systems have been investigated as potential targets for antiobesity drug development. Progress has been made in developing long-acting peptide analogs and, in some cases, nonpeptide agonists and antagonists. Whether any individual approach will have significant long-term efficacy remains to be demonstrated. Approaches that target multiple systems may hold the most promise.

UR - http://www.scopus.com/inward/record.url?scp=66649134711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66649134711&partnerID=8YFLogxK

U2 - 10.1210/en.2009-0003

DO - 10.1210/en.2009-0003

M3 - Article

C2 - 19372201

AN - SCOPUS:66649134711

VL - 150

SP - 2526

EP - 2530

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 6

ER -